Elizabeth McFarland, MD
Professor, Pediatrics-Infectious Diseases

Photo
Medical School:
  • MD, Duke University School of Medicine (1985)
Undergraduate School:
  • BS, Northwestern University (IL) (1981)
Internship:
  • University of Colorado (University Hospital) Program (1986)
Residency:
  • University of Colorado (University Hospital) Program, Pediatrics (1988)
Fellowships:
  • University of Colorado (University Hospital) Program, Pediatric Infectious Diseases (1992)
Languages: English
Department: Pediatrics-Infectious Diseases

Professional Titles

  • Section Chief, Pediatric Infectious Diseases
  • Medical Director, Children's Hospital Colorado HIV Program
  • Professor of Pediatrics

Research Interests

Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.

Publications

  • Dugdale CM, Ufio O, Alba C, Permar SR, Stranix-Chibanda L, Cunningham CK, Fouda GG, Myer L, Weinstein MC, Leroy V, McFarland EJ, Freedberg KA, Ciaranello AL. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. J Int AIDS Soc. 2023 Jan;26(1):e26052. PubMed PMID: 36604316
  • Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):153-161. PubMed PMID: 36215957
  • Alba C, Malhotra S, Horsfall S, Barnhart ME, Bekker A, Chapman K, Cunningham CK, Fast PE, Fouda GG, Freedberg KA, Goga A, Ghazaryan LR, Leroy V, Mann C, McCluskey MM, McFarland EJ, Muturi-Kioi V, Permar SR, Shapiro R, Sok D, Stranix-Chibanda L, Weinstein MC, Ciaranello AL, Dugdale CM. Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study. medRxiv. 2023 Nov 7. PubMed PMID: 37986879
  • Abuogi L, Smith C, Kinzie K, Barr E, Bonham A, Johnson RL, Dinnebeil M, McFarland E, Weinberg A. Development and Implementation of an Interdisciplinary Model for the Management of Breastfeeding in Women With HIV in the United States: Experience From the Children's Hospital Colorado Immunodeficiency Program. J Acquir Immune Defic Syndr. 2023 Aug 15;93(5):395-402. PubMed PMID: 37104739
  • Dugdale CM, Ufio O, Alba C, Permar SR, Stranix-Chibanda L, Cunningham CK, Fouda GG, Myer L, Weinstein MC, Leroy V, McFarland EJ, Freedberg KA, Ciaranello AL. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. J Int AIDS Soc. 2023 Jan;26(1):e26052. PubMed PMID: 36604316
  • Melvin AJ, Yee KL, Gray KP, Yedla M, Wan H, Tobin NH, Teppler H, Campbell H, McCarthy K, Scheckter R, Aurpibul L, Ounchanum P, Rungmaitree S, Cassim H, McFarland E, Flynn P, Cooper E, Krotje C, Townley E, Moye J, Best BM. Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014. J Acquir Immune Defic Syndr. 2023 Feb 1;92(2):153-161. PubMed PMID: 36215957
  • Cunningham CK, Karron RA, Muresan P, Kelly MS, McFarland EJ, Perlowski C, Libous J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, Johnston B, Chadwick EG, Cielo M, Paul M, Deville JG, Aziz M, Yang L, Luongo C, Collins PL, Buchholz UJ. Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV/?NS2/?1313/I1314L and RSV/276 in RSV-Seronegative Children. J Infect Dis. 2022 Dec 13;226(12):2069-2078. PubMed PMID: 35732186
  • Patel K, Huo Y, Jao J, Powis KM, Williams PL, Kacanek D, Yee LM, Chadwick EG, Shiau S, Jacobson DL, Brummel SS, Sultan-Beyer L, Kahlert CR, Zash R, Seage GR 3rd. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med. 2022 Sep 1;387(9):799-809. PubMed PMID: 36053505
  • 26. Smith C and McFarland EJ. Diagnosis and Clinical Manifestations of HIV Infection. In: Principles and Practice of Pediatric Infectious Diseases, 6th edition. Ed. Long SS, Prober CG, Fischer M, and Kimberlin DW. Elsevier, Inc.
  • Smith C and McFarland EJ. Human Immunodeficiency Virus (HIV) infection (acquired Immunodeficiency Syndrome [AIDS]). In: Current Pediatric Diagnosis & Treatment, 26th edition. Ed. Hay B, Abzug MA, RR Deterding. Appleton &Lange Inc, Norwalk,
  • Dirajlal-Fargo S, Williams PL, Broadwell C, McFARLAND EJ, Powis KM, Jacobson DL, Jao J. Youth living with perinatally-acquired HIV have lower physical activity levels as they age compared to HIV-exposed uninfected youth. J Acquir Immune Defic Syndr. 2021 Jan 13. [Epub ahead of print] PubMed PMID: 33443964
  • Gojanovich GS, Jacobson DL, Broadwell C, Karalius B, Kirmse B, Geffner ME, Jao J, Van Dyke RB, McFarland EJ, Silio M, Crain M, Gerschenson M. Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C. PLoS One. 2021;16(12):e0261563. PubMed PMID: 34972147
  • Lucier A, Fong Y, Li SH, Dennis M, Eudailey J, Nelson A, Saunders K, Cunningham CK, McFarland E, McKinney R, Moody MA, LaBranche C, Montefiori D, Permar SR, Fouda GG. Frequent development of broadly neutralizing antibodies in early life in a large cohort of children living with HIV. J Infect Dis. 2021 Dec 28. [Epub ahead of print] PubMed PMID: 34962990
  • Shiau S, Yu W, Jacobson DL, Nichols S, McFarland EJ, Chen JS, Dirajlal-Fargo S, Surowiec K, Geffner ME, Jao J. Components of metabolic syndrome associated with lower neurocognitive performance in youth with perinatally acquired HIV and youth who are HIV-exposed uninfected. J Neurovirol. 2021 Oct;27(5):702-715. PubMed PMID: 34524627
  • McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, Smith B, Hazra R, Purdue L, Harding PA, Theron G, Mujuru H, Agwu A, Purswani M, Rathore MH, Flach B, Taylor A, Lin BC, McDermott AB, Mascola JR, Graham BS. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. J Infect Dis. 2021 Dec 1;224(11):1916-1924. PubMed PMID: 34009371
  • Graff K, Smith C, Silveira L, Jung S, Curran-Hays S, Jarjour J, Carpenter L, Pickard K, Mattiucci M, Fresia J, McFarland EJ, Dominguez SR, Abuogi L. Risk Factors for Severe COVID-19 in Children. Pediatr Infect Dis J. 2021 Apr 1;40(4):e137-e145. PubMed PMID: 33538539
  • Dirajlal-Fargo S, Williams PL, Broadwell C, McFarland EJ, Powis KM, Jacobson DL, Jao J. Brief Report: Youth Living With Perinatally Acquired HIV Have Lower Physical Activity Levels as They Age Compared With HIV-Exposed Uninfected Youth. J Acquir Immune Defic Syndr. 2021 May 1;87(1):700-705. PubMed PMID: 33443964
  • Karron RA, Atwell JE, McFarland EJ, Cunningham CK, Muresan P, Perlowski C, Libous J, Spector SA, Yogev R, Aziz M, Woods S, Wanionek K, Collins PL, Buchholz UJ. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children. Am J Respir Crit Care Med. 2021 Mar 1;203(5):594-603. PubMed PMID: 32871092
  • Li J, Nikanjam M, Cunningham CK, McFarland EJ, Coates EE, Houser KV, Lin BC, McDermott AB, Flach B, Gama L, Koup RA, Graham BS, Mascola JR, Ledgerwood JE, Capparelli EV. Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clin Pharmacol Ther. 2021 Jan;109(1):184-192. PubMed PMID: 32866318
  • Gojanovich GS, Jacobson DL, Broadwell C, Karalius B, Kirmse B, Geffner ME, Jao J, Van Dyke RB, McFarland EJ, Silio M, Crain M, Gerschenson M. Associations of FGF21 and GDF15 with mitochondrial dysfunction in children living with perinatally-acquired HIV: A cross-sectional evaluation of pediatric AIDS clinical trials group 219/219C. PLoS One. 2021;16(12):e0261563. PubMed PMID: 34972147
  • Karron RA, Atwell JE, McFarland EJ, Cunningham CK, Muresan P, Perlowski C, Libous J, Spector SA, Yogev R, Aziz M, Woods S, Wanionek K, Collins PL, Buchholz UJ. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children. Am J Respir Crit Care Med. 2020 Sep 1. [Epub ahead of print] PubMed PMID: 32871092
  • Li J, Nikanjam M, Cunningham CK, McFarland EJ, Coates EE, Houser KV, Lin BC, McDermott AB, Flach B, Gama L, Koup RA, Graham BS, Mascola JR, Ledgerwood JE, Capparelli EV. Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. Clin Pharmacol Ther. 2020 Aug 31. [Epub ahead of print] PubMed PMID: 32866318
  • McFarland EJ, Karron RA, Muresan P, Cunningham CK, Perlowski C, Libous J, Oliva J, Jean-Philippe P, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Cielo M, Wiznia A, Deville JG, Yang L, Luongo C, Collins PL, Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children. J Infect Dis. 2020 Jun 11;221(12):2050-2059. PubMed PMID: 32006006
  • McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski C, Thumar B, Gnanashanmugam D, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Spector SA, Aziz M, Cielo M, Beneri C, Wiznia A, Luongo C, Collins P, Buchholz UJ. Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children. J Infect Dis. 2020 Feb 3;221(4):534-543. PubMed PMID: 31758177
  • Cunningham CK, McFarland EJ, Morrison RL, Capparelli EV, Safrit JT, Mofenson LM, Mathieson B, Valentine ME, Perlowski C, Smith B, Hazra R, Purdue L, Muresan P, Harding PA, Mbengeranwa T, Robinson LG, Wiznia A, Theron G, Lin B, Bailer RT, Mascola JR, Graham BS. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. J Infect Dis. 2020 Jul 23;222(4):628-636. PubMed PMID: 31681963
  • McFarland EJ, Karron RA, Muresan P, Cunningham CK, Libous J, Perlowski C, Thumar B, Gnanashanmugam D, Moye J, Schappell E, Barr E, Rexroad V, Fearn L, Spector SA, Aziz M, Cielo M, Beneri C, Wiznia A, Luongo C, Collins P, Buchholz U. Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030s is a promising vaccine candidate in children. J Infect Dis. 2019 Nov 23. [Epub ahead of print] PubMed PMID: 31758177
  • Cunningham CK, McFarland EJ, Morrison RL, Capparelli EV, Safrit JT, Mofenson LM, Mathieson B, Valentine ME, Perlowski C, Smith B, Hazra R, Purdue L, Muresan P, Harding PA, Mbengeranwa T, Robinson LG, Wiznia A, Theron G, Lin B, Bailer RT, Mascola JR, Graham BS. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. J Infect Dis. 2019 Nov 4. [Epub ahead of print] PubMed PMID: 31681963
  • Cunningham CK, Karron R, Muresan P, McFarland EJ, Perlowski C, Libous J, Thumar B, Gnanashanmugam D, Moye J Jr, Schappell E, Barr E, Rexroad V, Aziz M, Deville J, Rutstein R, Yang L, Luongo C, Collins P, Buchholz U. Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated. Open Forum Infect Dis. 2019 Jun;6(6):ofz212. PubMed PMID: 31211158
  • Jao J, Jacobson DL, Yu W, Borkowsky W, Geffner ME, McFarland EJ, Patel K, Williams PL, Miller T. A Comparison of Metabolic Outcomes Between Obese HIV-Exposed Uninfected Youth From the PHACS SMARTT Study and HIV-Unexposed Youth From the NHANES Study in the United States. J Acquir Immune Defic Syndr. 2019 Jul 1;81(3):319-327. PubMed PMID: 30844997
  • Lally MA, van den Berg JJ, Westfall AO, Rudy BJ, Hosek SG, Fortenberry JD, Monte D, Tanney MR, McFarland EJ, Xu J, Kapogiannis BG, Wilson CM. HIV Continuum of Care for Youth in the United States. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):110-117. PubMed PMID: 28991884
  • McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, Thumar B, Gnanashanmugam D, Siberry GK, Schappell E, Barr E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, Collins PL, Buchholz UJ. Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children. J Infect Dis. 2018 Apr 11;217(9):1347-1355. PubMed PMID: 29509911
  • Jao J, Yu W, Patel K, Miller TL, Karalius B, Geffner ME, DiMeglio LA, Mirza A, Chen JS, Silio M, McFarland EJ, Van Dyke RB, Jacobson D. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study. HIV Med. 2018 Mar;19(3):175-183. PubMed PMID: 29159965
  • McGuire EP, Fong Y, Toote C, Cunningham CK, McFarland EJ, Borkowsky W, Barnett S, Itell HL, Kumar A, Gray G, McElrath MJ, Tomaras GD, Permar SR, Fouda GG. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. J Virol. 2018 Jan 1;92(1). PubMed PMID: 29021402
  • Lally MA, van den Berg JJ, Westfall AO, Rudy BJ, Hosek SG, Fortenberry JD, Monte D, Tanney MR, McFarland EJ, Xu J, Kapogiannis BG, Wilson CM. HIV Continuum of Care for Youth in the United States. J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):110-117. PubMed PMID: 28991884
  • Itell HL, McGuire EP, Muresan P, Cunningham CK, McFarland EJ, Borkowsky W, Permar SR, Fouda GG. Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. Vaccine. 2018 Sep 5;36(37):5600-5608. PubMed PMID: 30087048
  • Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry GK, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron RA. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children. J Infect Dis. 2018 Apr 11;217(9):1338-1346. PubMed PMID: 29509929
  • Agwu AL, Warshaw MG, McFarland EJ, Siberry GK, Melvin AJ, Wiznia AA, Fairlie L, Boyd S, Harding P, Spiegel HML, Abrams EJ, Carey VJ. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. PLoS One. 2017;12(6):e0178075. PubMed PMID: 28604824
  • Warshaw MG, Carey VJ, McFarland EJ, Dawson L, Abrams E, Melvin A, Fairlie L, Spiegel H, Jay J, Agwu AL. The interaction between equipoise and logistics in clinical trials: A case study. Clin Trials. 2017 Jun;14(3):314-318. PubMed PMID: 28135804
  • Jacobson DL, Patel K, Williams PL, Geffner ME, Siberry GK, DiMeglio LA, Crain MJ, Mirza A, Chen JS, McFarland E, Kacanek D, Silio M, Rich K, Borkowsky W, Van Dyke RB, Miller TL. Growth at 2 Years of Age in HIV-exposed Uninfected Children in the United States by Trimester of Maternal Antiretroviral Initiation. Pediatr Infect Dis J. 2017 Feb;36(2):189-197. PubMed PMID: 27798548
  • Messacar K, Dunn J, Khan TZ, Etcheverry A, McFarland EJ, Dominguez SR. Diffuse Nodular Lung Infiltrates in a Well Appearing Three-Year-Old Boy With Recurrent Sinopulmonary Infections and Parotitis. J Pediatric Infect Dis Soc. 2015 Mar;4(1):74-7. PubMed PMID: 26407362
  • Williams PL, Abzug MJ, Jacobson DL, Wang J, Van Dyke RB, Hazra R, Patel K, Dimeglio LA, McFarland EJ, Silio M, Borkowsky W, Seage GR 3rd, Oleske JM, Geffner ME, International Maternal Pediatric and Adolescent AIDS Clinical Trials P219219C Study and the Pediatric HIVAIDS Cohort Study. Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment. AIDS. 2013 Jul 31;27(12):1959-70. PubMed PMID: 24145244
  • Sharma TS, Jacobson DL, Anderson L, Gerschenson M, Van Dyke RB, McFarland EJ, Miller TL, Pediatric HIV/AIDS Cohort Study (PHACS). Short communication: The relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy. AIDS Res Hum Retroviruses. 2013 Sep;29(9):1211-7. PubMed PMID: 23742635
  • Miller TI, Borkowsky W, DiMeglio LA, Dooley L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, Siberry GK, Van Dyke RB, Worrell CJ, Jacobson DL, Pediatric HIV/AIDS Cohort Study (PHACS), Shearer W, Cooper N, Harris L, Purswani M, Baig M, Cintron A, Puga A, Navarro S, Patton D, Burchett S, Karthas N, Kammerer B, Yogev R, Malee K, Hunter S, Cagwin E, Wiznia A, Burey M, Nozyce M, Chen J, Gobs E, Grant M, Knapp K, Allison K, Garvie P, Acevedo-Flores M, Rios H, Olivera V, Silio M, Borne C, Sirois P, Spector S, Norris K, Nichols S, McFarland E, Barr E, Chambers C, Watson D, Messenger N, Belanger R, Dieudonne A, Bettica L, Adubato S, Scott G, Himic L, Willen E. Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children. HIV Med. 2012 May;13(5):264-75. PubMed PMID: 22136114
  • C Smith-Anderson and EJ McFarland, Diagnosis and Clinical Manifestations of HIV Infection, in Principles and Practice of Pediatric Infectious Diseases, 6e Edited by Sarah S Long, Charles G Prober, Marc Fischer, and David W. Kimberlin
View All (44 Total) View Less

Professional Memberships

  • Pediatric Infectious Disease Society, Member

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234

Hospital Affiliation
  • Children's Hospital Colorado

Specialty Information

Specialties
  • Pediatric Infectious Diseases, Board Certification (1992, 2008)
  • Pediatrics, Board Certification (1990, 2014)
Conditions & Treatments
  • Immune System - AIDS / HIV Disease
  • Immune System - AIDS Immunization
  • Infections - Bacterial Infections
  • Infections - Fungal Infections
  • Infections - Influenza
  • Infections - Pneumonia
  • Infections - Viral Infections
  • Infections
  • Immune System - AIDS
  • Symptoms and Manifestations - Fever
  • Immune System
  • Symptoms and Manifestations
  • Kawasaki Disease
Clinical Interests
I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.

General Information

Medical Schools:
  • MD, Duke University School of Medicine (1985)
Undergraduate Schools:
  • BS, Northwestern University (IL) (1981)
Internships:
  • University of Colorado (University Hospital) Program (1986)
Residency Programs:
  • University of Colorado (University Hospital) Program, Pediatrics (1988)
Fellowships:
  • University of Colorado (University Hospital) Program, Pediatric Infectious Diseases (1992)
Languages: English
Department: Pediatrics-Infectious Diseases
Contact Us
CU Anschutz
Fitzsimons Building

13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;